MicroRNA-34a通过上调Cdc42和Rac1促进人晶状体上皮细胞衰老和凋亡

目的:观察MicroRNA-34a对人晶状体上皮细胞系SRA01/04衰老和凋亡的影响及作用机制。方法:qRT-PCR检测年龄相关性白内障(ARC)晶状体和透明晶状体上皮细胞中MicroRNA-34a表达水平,采用脂质体转染试剂盒将MicroRNA-34a mimics(过表达组)、MicroRNA-34a inhibitors(抑制组)和空脂质体(对照组)转染至SRA01/04细胞,qRT-PCR检测MicroRNA-34a的表达量;采用β-半乳糖苷酸(SA-β-gal)染色检测转染后细胞的衰老情况。Annexin V-FITC/PI双染色流式细胞仪检测MicroRNA-34a对人晶状体细胞系SRA01/04细胞凋亡的影响;蛋白免疫印迹检测Cdc42、Rac1蛋白的表达。结果:透明晶状体前囊膜组织中MicroRNA-34a的表达量显著低于ARC晶状体前囊膜组织(P<0.05);MicroRNA-34a过表达组、对照组、MicroRNA-34a抑制组SA-β-gal阳性率分别为(87.56±2.34)%、(12.22±2.74)%、(3.45±0.45)%。MicroRNA-34a过表达组明显高于对照组,而MicroRNA-34a抑制组SA-β-gal阳性率明显低于对照组(P<0.05);MicroRNA-34a抑制组、对照组和MicroRNA-34a过表达组的细胞凋亡率分别为(5.87±1.22)%、(12.26±2.14)%、(29.45±3.12)%,MicroRNA-34a抑制组细胞凋亡率明显低于对照组,而MicroRNA-34a过表达组细胞凋亡率明显高于对照组(P<0.05);MicroRNA-34a过表达组中Cdc42和Rac1的表达明显高于对照组(P<0.05),MicroRNA-34a抑制组中Cdc42和Rac1的表达明显低于对照组(P<0.05)。结论:MicroRNA-34a可能通过上调Cdc42和Rac1促进人晶状体上皮细胞衰老和凋亡。     

Potassium 2-（1-hydroxypentyl）-benzoate promotes long-term potentiation in Aβ1-42-injected rats and APP/PS1 transgenic mice

Aim： Potassium 2-（1-hydroxypentyl）-benzoate （d/-PHPB） is a new drug candidate for ischemic stroke. The aim of this study was to investigate the effects of dI-PHPB on memory deficits and long-term potentiation （LTP） impairment in animal models of Alzheimer＇s disease. Methods： The expression of NMDA receptor subunits GluN1 and GluN2B in the hippocampus and cortex of APP/PS1 transgenic mice were detected using Western blot analysis. Memory deficits of the mice were evaluated with the passive avoidance test. LTP impairment was studied in the dentate region of Aβ1-42-injected rats and APP/PS1 transgenic mice. Results： APP/PS1 transgenic mice showed significantly lower levels of GluN1 and p-GluN2B in hippocampus, and chronic administration of dI-PHPB （100 mg·kg-1·d1, po） reversed the downregulation of p-GluN2B, but did not change GluN1 level in the hippocampus. Furthermore, chronic administration of d/-PHPB reversed the memory deficits in APP/PS1 transgenic mice. In the dentate region of normal rats, injection of dI-PHPB （100 μmol/L, icv） did not change the basal synaptic transmission, but significantly enhanced the high-frequency stimulation （HFS）-induced LTP, which was completely prevented by pre-injection of APV （150 μmol/L, icv）. Chronic administration of dI-PHPB （100 mg·kg-1·d-1, po） reversed LTP impairment in Aβ1-42 -injected normal rats and APP/PS1 transgenic mice. Conclusion： Chronic administration of d/-PHPB improves learning and memory and promotes LTP in the animal models of Alzheimer＇s disease, possibly via increasing p-GluN2B expression in the hippocampus.     

Cdc42: Role in Cancer Management

Contribution of Cdc42, a member of Rho family, has been characterized for the beginning of variety of cellular responses including cellular transformation, cell division, cell invasion, migration, invadopodia formation, enzyme activity, filopodia formation, and cell polarity in cells. Deregulation of Cdc42 can alter the normal functioning of the cells, responsible for the initiation of signaling pathways and is correlated with several pathogenic processes such as cancer. Therefore, maintaining the level of Cdc42 and its effectors in cells, tumor progression can be controlled. Therefore, it can be suggested that deeper understanding about the Cdc42 contribution in cancer cell progression at molecular level can approach to the development of Cdc42 inhibitors in cancer management.     

Lithium therapy and cerebrospinal fluid biomarker levels in Alzheimer's disease

Recent studies suggest that lithium may retard pathological deterioration by inhibiting aberrant phosphorylation of tau in Alzheimer's disease (AD). Here, we describe three cases of AD who were treated with lithium for agitation. However, there was no obvious improvement either in global cognition, agitation or cerebrospinal fluid markers that were thought to reflect Alzheimer's pathology. Increased dosages of lithium were not tolerated by the patients because of adverse effects. It is likely that AD patients do not benefit from lithium therapy as an alternative choice of treatment.     

Antiproliferative effects of interferonγ in combination withα-difluoromethylornithine on human carcinoma cell cultures

The antiproliferative effects of human recombinant interferon (IFN) in combination with -difluoromethylornithine (DFMO) or as single agents were assessed on human cell cultures derived from carcinomas of the breast (MCF-7), the ovary (EFO-27) or the kidneys (EGI-4). Results were obtained in proliferation assays by direct cell counting. The cell lines differed considerably in their sensitivities to the antiproliferative effect of IFN as compared by the 50% inhibition doses of the growth (ID₅₀). In contrast to the findings with IFN, similar antiproliferative effects resulted from the application of comparable doses of DFMO. While IFN induced cytotoxic effects in EGI-4 cells, DFMO produced only cytostatic actions in the cell lines analyzed. Synergistic growth inhibition resulted from the combined application of IFN and DFMO in EFO-27 cell cultures. This finding was most pronounced after treatment with IFN or DFMO doses below the respective ID₅₀ values. However, antagonistic effects occurred in cells of the line EGI-4 after DFMO had been combined with IFN at concentrations below the cytotoxic dose range. Within the sensitivity of our proliferation assay, no synergistic interactions were found in MCF-7 cell cultures. In the cell lines tested, no relation between the sensitivity for the single agents and the effectivity of the drug combination was identified. Despite promising synergistic effects in the moderately IFN-sensitive ovarian carcinoma cell line EFO-27, the efficacy of the IFN/DFMO combination was restrained by possible antagonistic effects as demonstrated in the highly IFN-sensitive EGI-4 renal carcinoma cell cultures. We conclude that the differential interaction patterns in the cell cultures analyzed preclude general suggestions for clinical studies using IFN and DFMO.Abbreviations IFN interferon - DFMO difluoromethylornithine This work was part of the doctoral thesis of Mariam Klouche     

Involvement of cysteinyl leukotriene receptor 1 in Aβ1–42-induced neurotoxicity in vitro and in vivo

Accumulation of amyloid-β (Aβ) is thought to be associated with the progressive neuronal death observed in Alzheimer's disease, but the mechanisms underlying neurotoxicity triggered by Aβ remain elusive. In the current study, we investigated the roles of cysteinyl leukotriene receptor 1 (CysLT₁R) in Aβ_1–42-induced neurotoxicity in vitro or in vivo. In vitro exposure of mouse primary neurons to Aβ_1–42 caused a gradual increases in CysLT₁R expression. In vivo bilateral intrahippocampal injection of Aβ_1–42 also elicited time-dependent increases of CysLT₁R expression in the hippocampus and cortex of mice. The CysLT₁R antagonist pranlukast not only reversed Aβ_1–42-induced upregulation of CysLT₁R, but also suppressed Aβ_1–42-triggered neurotoxicity evidenced by enhanced nuclear factor-kappa B p65, activated caspase-3, decreased B-cell lymphoma-2 and cell viability and impaired memory. Furthermore, chronic treatment with pranlukast produced similar beneficial effects on memory behavior and hippocampal long-term potentiation to memantine or donepezil in intrahippocampal Aβ_1–42-injected mice. Our data indicate that CysLT₁R is involved in Aβ_1–42-induced neurotoxicity, and that blockade of CysLT₁R, such as application of CysLT₁R antagonist, could be a novel and promising strategy for the treatment of Alzheimer's disease.     

Norepinephrine provides short-term neuroprotection against Aβ1–42 by reducing oxidative stress independent of Nrf2 activation

Pathophysiological evidence correlating locus ceruleus neuron loss with increased Alzheimer's disease pathology suggests that norepinephrine (NE) is neuroprotective. Here, we evaluated the effects of NE on amyloid-β (Aβ)1-42–induced neurotoxicity and determined how NE exerts its actions in human SK-N-SH neurons. NE protected SK-N-SH cells against Aβ1-42–induced neurotoxicity only after a 4-hour treatment. The ability of NE to reduce Aβ1-42–induced neurotoxicity was independent of the adrenoceptor signaling pathway. Notably, NE downregulated Aβ1-42–mediated increases in intracellular reactive oxygen species (ROS) production. However, NE did not affect Aβ1-42–induced activation of the nuclear factor erythroid 2–related factor 2 (Nrf2) redox signaling pathway, known to be involved in oxidative stress. Among the antioxidants tested, N-acetyl cysteine and glutathione, which are not only ROS scavengers but also thiol-reducing agents, mimicked the protective effects of NE. Consistently, Kelch-like ECH-associating protein 1 inhibitors, which activated the Nrf2 pathway, failed to decrease Aβ1-42–induced ROS generation and elicited no protection against Aβ1–42. Taken together, these findings suggest that NE could exert neuroprotective function against Aβ1–42 via redox cycling and reduction of intracellular oxidative stress regardless of downstream activation of the Nrf2 pathway.     

基于JAK2/STAT3信号通路探讨大黄素保护AR42J胰腺腺泡细胞损伤的作用机制

目的基于JAK2/STAT3信号通路探讨大黄素保护AR42J胰腺腺泡细胞损伤的作用机制。方法将AR42J细胞以1×10~5/mL铺于6孔板,分为对照组、雨蛙素组(雨蛙素10~(-8) mol/L)、大黄素组(终浓度0.25、0.5、1.0mg/L),通过碘-淀粉比色法淀粉酶(AMS)试剂盒测定细胞上清淀粉酶活力水平,确定雨蛙素刺激AR42J胰腺腺泡细胞损伤的收样时间;ELISA法检测TNF-α活力;Western blot法分析JAK2/STAT3通路相关蛋白的表达情况。结果①与对照组比较,雨蛙素组中的AMS、TNF-α、JAK2/STAT3通路相关蛋白表达量显著提高,差异有统计学意义(P0.05)。②与雨蛙素组比较,大黄素各干预组可显著降低雨蛙素诱导的胰腺腺泡细胞损伤的淀粉酶活力、TNF-α含量、JAK2和STAT3的mRNA相对表达量,差异有统计学意义(P0.01)。③大黄素0.5、1.0 mg/L干预组的作用优于0.25 mg/L干预组,差异有统计学意义(P0.001)。结论大黄素能够减轻雨蛙素诱导的胰腺腺泡细胞损伤,其作用机制可能与调控JAK2/STAT3信号通路有关。     

分化抗原gp42在人免疫细胞的表达

目的　明确gp4 2蛋白为分化抗原 ,检测它在人免疫细胞的表达。方法　用gp4 2蛋白免疫小鼠 ,制备抗gp4 2蛋白的单抗。用反义技术制备gp4 2蛋白表达抑制的 3D5细胞。用免疫荧光染色和Western印迹确定gp4 2单抗的特异性。用胞膜蛋白免疫沉淀和流式细胞术确定gp4 2蛋白为分化抗原。用双色免疫荧光染色流式细胞术检测gp4 2分化抗原在多种人免疫细胞的表达。结果　制备了抗gp4 2蛋白的特异性单抗。用gp4 2单抗作探针 ,从 3D5细胞膜免疫沉淀到相对分子质量 (Mr)为4 2 0 0 0的一条蛋白带 ,并在活 3D5细胞见阳性免疫荧光染色。gp4 2分化抗原在人外周围血CD19+ 、CD14 + 、CD4 + 、CD8+ 和CD5 6 + 细胞的表达率分别为 5 9.71%± 11.36 %、89.0 8%± 4 .87%、2 6 .0 3%±9.75 %、2 4 .2 4 %± 15 .2 9%和 2 4 .2 0 %± 15 .72 % ,在人免疫细胞株的表达率分别为 5 8.0 % (Nalm6 )、72 .7% (3D5 )、5 3.6 % (BJAB)、6 1.0 % (Daudi)、6 .9% (SKW6 )、6 .3% (Jurkat)、5 .8% (Peer)、2 1.3% (K5 6 2 )和 39.1% (U937)。结论　gp4 2蛋白为一个分化抗原 ,在人外周围血CD14 + 细胞的表达率最高 ,其次为CD19+ 细胞 ,CD4 + 、CD8+ 和CD5 6 + 细胞的表达率较低。